Nadolol

It is a nonselective beta-adrenergic antagonist used for the treatment of arrhythmias, angina pectoris, and hypertension. Oral administration once daily.

In spite of its low percentage of fixation to plasma proteins, its not very high molecular weight and long half-life, which facilitate the passage into breast milk ^{(Riant 1986)}, it is excreted in breast milk in small quantities ^{(Fox 1985, Devlin 1981)}, perhaps due to its very wide volume of distribution which makes it difficult to do so.

Two mothers taking nadolol during pregnancy and breastfeeding reported no clinical problems in their breastfed infants. ^{(Freppel 2024)}

Its low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.

Some authors consider it a safe medication during breastfeeding ^{(Pringsheim 2012)}. American Academy of Pediatrics: medication usually compatible with breastfeeding. ^{(AAP 2001)}

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable ^{(Davanzo 2014, Mahadevan 2006)}, especially during the neonatal period and in the event of prematurity.